July 4, 2012Open Access

Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 ( HER2 ) Tyrosine Kinase Mutations in Lung Adenocarcinomas

Key Points

Key points are not available for this paper at this time.

Abstract

HER2 mutations identify a distinct subset of lung ADCs. Given the high prevalence of lung cancer worldwide and the availability of standard and investigational therapies targeting HER2, routine clinical genotyping of lung ADC should include HER2.

Bookmark

View Full Paper

Cite This Study

Arcila et al. (Wed,) studied this question.

synapsesocial.com/papers/699aeb352dac970dae1eb0a8 https://doi.org/https://doi.org/10.1158/1078-0432.ccr-12-0912

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers2011 · 148 citations
2Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains2011 · 94 citations
3Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases2010 · 332 citations
4Rapid Polymerase Chain Reaction-Based Detection of Epidermal Growth Factor Receptor Gene Mutations in Lung Adenocarcinomas2005 · 248 citations
5Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu2012 · 277 citations

Bookmark

View Full Paper